



Pharmacy News – PDL Update July 2023

As of July 2023, AHCA (Agency for Healthcare Administration) in Florida has designated brand Remicade 100mg vial (Infliximab) to be non-preferred. This means a prior authorization is now required for the branded product.

AHCA now designates its ***generic equivalent*** (Infliximab 100mg vial) as preferred. Infliximab does NOT require a prior authorization to be submitted. Please consider switching to this AHCA preferred alternative at the earliest.

If you need further assistance, please contact Molina Healthcare at: 855-322-4076, Monday through Friday,
8am – 5pm.

Thank you for your continued care to our members!

Molina Healthcare of Florida